Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.77 |
| ▸ | NOS1 | P29475 | 2/20 | 0.77 |
| ▸ | NOS2 | P35228 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075410 | 0.87 | NOS3 (1.00) | NOS3NOS1NOS2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8324907 | 0.85 | NOS3 (0.96) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL84394 | 0.76 | NOS3 (0.65) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL12066839 | 0.75 | NOS3 (0.48) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL14999656 | 0.75 | TSHR (0.52) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL22983751 | 0.73 | NOS3 (0.57) | NOS3NOS1NOS2NPC1RAB9A | |
| SCHEMBL23443665 | 0.72 | MAPT (0.49) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL519052 | 0.71 | CYP2A6 (0.45) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL692287 | 0.71 | NOS3 (0.44) | NOS3NOS1NOS2TSHRNPC1 | |
| SCHEMBL7618082 | 0.71 | NPC1 (0.45) | NOS3NOS1NOS2TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4013456-A1 | FORMULATIONS OF BENZAZEPINE CONJUGATES AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2021-09-09 | — | — | US | disclosed |
| US-20210077632-A1 | Formulations of Benzazepine Conjugates and Uses Thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2021030665-A1 | FORMULATIONS OF BENZAZEPINE CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030665-A1 | FORMULATIONS OF BENZAZEPINE CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077632-A1 | Formulations of Benzazepine Conjugates and Uses Thereof | BDNF, FURIN, VGF | NOS3 3772/4885NOS1 4146/4885NOS2 4013/4885 |
| US-20210275683-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, SIGLEC7, CD2 | NOS3 3653/4885NOS1 4263/4885NOS2 4043/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | NOS3 2517/4885NOS1 2206/4885NOS2 2419/4885 |
| US-11179473-B2 | Nectin-4 antibody conjugates and uses thereof | NECTIN4, SIGLEC7, CD2 | NOS3 3653/4885NOS1 4263/4885NOS2 4043/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | NOS3 2277/4885NOS1 1744/4885NOS2 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.